Funda Aksu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Funda Aksu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Kurtuluş Aksu
Department of Allergy and Clinical Immunology, Ankara Atatürk Sanatorium Training and Research Hospital, University of Health Sciences, Ankara 06290, Türkiye
10 shared publications - Sezgi Şahin Duyar
Department of Chest Diseases, University of Health Sciences Sincan Education and Research Hospital Gökçek, Sincan/Ankara, Türkiye
5 shared publications - Selma Fırat
Sleep Disorders Center, Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
4 shared publications - Deniz Çelik
Department of Pulmonary Medicine, Faculty of Medicine, Alanya Alaaddin Keykubat University, 07425 Antalya, Turkey
3 shared publications - Gürgün Tuğçe Vural Solak
Division of Immunology and Allergy, Department of Chest Diseases, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkiye
3 shared publications - Fatma Dindar Çelik
University of Health Sciences, Ankara Ataturk Sanatoryum Training and Research Hospital, Department of Immunology and Allergy, Ankara, Türkiye., Ankara, Türkiye
2 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (2) , 509-517
Asthma data in Türkiye between 2016 and 2022: a nationwide descriptive and observational study covering the entire adult population
Background/aim: Determining the current burden of asthma in countries is important in the diagnosis and follow-up of asthma patients and for the development of national health policies. Our study aimed to clarify the epidemiological and clinical data regarding asthmatic adults in Türkiye. Materials and methods: The study was designed as a nationwide descriptive, observational cross-sectional study. Data on adult patients who were followed with the diagnosis of asthma in all public, private, and university hospitals in Türkiye between January 2016 and December 2022 were obtained from the e-Nabız database of the Ministry of Health and analyzed. Results: The number of patients followed with a diagnosis of asthma in Türkiye between 2016 and 2022 was 2,700,183. The mean age of these patients was 45.70 years (standard deviation: 15.87) and 74.5% of them were female. Of the patients, 92.3% were prescribed dry powder inhalers, 98.41% metered dose inhalers, and 80.38% montelukast. The short-acting beta-2 agonist (SABA) prescription rate was 65.74% and SABA was prescribed as the sole medication for 0.10% of patients. The percentage of patients prescribed nebulized treatment was found to be 69.83%. Among asthmatic adults, the rate of at least one emergency room visit was 12.4%, the rate of hospitalization in the ward was 5.6%, and the rate of intensive care unit admission was 0.1%. Conclusion: Asthma is a major health burden in Türkiye, as is the case around the world. National planning for the diagnosis and follow-up of patients needs to be improved and continued.
- 14 April 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (2) , 509-517
Open AccessAsthma data in Türkiye between 2016 and 2022: a nationwide descriptive and observational study covering the entire adult population
Background/aim: Determining the current burden of asthma in countries is important in the diagnosis and follow-up of asthma patients and for the development of national health policies. Our study aimed to clarify the epidemiological and clinical data regarding asthmatic adults in Türkiye. Materials and methods: The study was designed as a nationwide descriptive, observational cross-sectional study. Data on adult patients who were followed with the diagnosis of asthma in all public, private, and university hospitals in Türkiye between January 2016 and December 2022 were obtained from the e-Nabız database of the Ministry of Health and analyzed. Results: The number of patients followed with a diagnosis of asthma in Türkiye between 2016 and 2022 was 2,700,183. The mean age of these patients was 45.70 years (standard deviation: 15.87) and 74.5% of them were female. Of the patients, 92.3% were prescribed dry powder inhalers, 98.41% metered dose inhalers, and 80.38% montelukast. The short-acting beta-2 agonist (SABA) prescription rate was 65.74% and SABA was prescribed as the sole medication for 0.10% of patients. The percentage of patients prescribed nebulized treatment was found to be 69.83%. Among asthmatic adults, the rate of at least one emergency room visit was 12.4%, the rate of hospitalization in the ward was 5.6%, and the rate of intensive care unit admission was 0.1%. Conclusion: Asthma is a major health burden in Türkiye, as is the case around the world. National planning for the diagnosis and follow-up of patients needs to be improved and continued.
- 30 July 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (10) , 2716-2720
An Investigation of Loneliness in Patients with Severe Asthma
- 30 July 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (10) , 2716-2720
An Investigation of Loneliness in Patients with Severe Asthma
- 8 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1584-1590
Efficacy of tiotropium bromide on spirometric measurements and control of asthma in real life: data from a 1-year clinical follow-up
Real-life studies are needed to evaluate the clinical outcomes of add-on tiotropium therapy in patients with asthma. The effects of adding tiotropium bromide to the treatment of asthmatic patients on pulmonary functions and asthma control using real-life data. In a retrospective study, spirometric measures and asthma control states were compared before and one year after of tiotropium treatment in asthmatic adults whose disease was not adequately controlled with a combination of inhaled corticosteroids and long-acting β2-agonists. One year after tiotropium treatment, mean FEV1, FEV1%, and FEV1/FVC ratio increased significantly compared to pretreatment values. Among 32 patients added tiotropium due to symptomatic asthma, 28 (87.5%) patients achieved well-controlled (ACT ≥ 20) end of the year and GINA treatment step-down in 4 (12.5%) patients. Monoclonal antibody therapies (mepolizumab or omalizumab) were initiated in 9 patients (28.1%). FEV1 values and FEV1/FVC ratios showed a statistically significant improvement from baseline measurements obtained prior to the initiation of tiotropium therapy, independent of monoclonal antibody use (p < 0.001 for each). The mean age of these patients was 48.78 ± 11.64 (range: 28 - 81) years, and 25 (78.1%) of them were female. Tiotropium bromide is an effective and reliable add-on therapy for symptomatic asthma when combined with ICS plus LABA, also leads to improvements in respiratory function and asthma control.
- 8 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1584-1590
Efficacy of tiotropium bromide on spirometric measurements and control of asthma in real life: data from a 1-year clinical follow-up
Real-life studies are needed to evaluate the clinical outcomes of add-on tiotropium therapy in patients with asthma. The effects of adding tiotropium bromide to the treatment of asthmatic patients on pulmonary functions and asthma control using real-life data. In a retrospective study, spirometric measures and asthma control states were compared before and one year after of tiotropium treatment in asthmatic adults whose disease was not adequately controlled with a combination of inhaled corticosteroids and long-acting β2-agonists. One year after tiotropium treatment, mean FEV1, FEV1%, and FEV1/FVC ratio increased significantly compared to pretreatment values. Among 32 patients added tiotropium due to symptomatic asthma, 28 (87.5%) patients achieved well-controlled (ACT ≥ 20) end of the year and GINA treatment step-down in 4 (12.5%) patients. Monoclonal antibody therapies (mepolizumab or omalizumab) were initiated in 9 patients (28.1%). FEV1 values and FEV1/FVC ratios showed a statistically significant improvement from baseline measurements obtained prior to the initiation of tiotropium therapy, independent of monoclonal antibody use (p < 0.001 for each). The mean age of these patients was 48.78 ± 11.64 (range: 28 - 81) years, and 25 (78.1%) of them were female. Tiotropium bromide is an effective and reliable add-on therapy for symptomatic asthma when combined with ICS plus LABA, also leads to improvements in respiratory function and asthma control.
- Open Access
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1281-1285
Implementation of written asthma action plan among asthma patients in Türkiye: a multicenter, cross-sectional, descriptive study
Background/aim: In our country, there is no data on whether the clinicians give an asthma action plan to implement to patients followed up with a diagnosis of asthma, and whether patients can manage their treatment according to this plan. The present study aimed to determine the use of asthma action plans in our country and the awareness levels of patients about the plan.Materials and methods: Multicenter, cross-sectional descriptive study was conducted in outpatient immunology and allergy and pulmonology clinics of secondary and tertiary health-care centers. Adults asthmatics filled out a case registration form regarding age, gender, educational status, duration of asthma, and smoking history. Subjects answered The Global Initiative for Asthma (GINA) assessment of control questions and whether they had previously been mentioned an asthma action plan and benefited from it. Results: Data of 265 asthmatic adults (mean age: 48.4 (standard deviation: 13.4) years, 194 (73.2%) females) were analyzed. The asthma control state of 212 (80.0%) patients was controlled, and 53 (20.0%) patients was uncontrolled. An asthma action plan was mentioned to 91 (34.3%) of 265 patients. Among these 91 patients who were mentioned about the asthma action plan, 85 (93.4%) were given written asthma action plan, 85 (93.4%) stated that they benefited from the plan. The rate of being given an asthma action plan in illiterate patients was significantly lower than in patients with any education (p<0.001).Conclusion: Rate of mentioning an asthma action plan to asthmatics is low. Almost all patients to whom an asthma action plan is recommended benefit significantly from the plan. It is important to give patients with asthma an asthma action plan. It would be even more useful to give this plan in written form.
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1281-1285
Open AccessImplementation of written asthma action plan among asthma patients in Türkiye: a multicenter, cross-sectional, descriptive study
Background/aim: In our country, there is no data on whether the clinicians give an asthma action plan to implement to patients followed up with a diagnosis of asthma, and whether patients can manage their treatment according to this plan. The present study aimed to determine the use of asthma action plans in our country and the awareness levels of patients about the plan.Materials and methods: Multicenter, cross-sectional descriptive study was conducted in outpatient immunology and allergy and pulmonology clinics of secondary and tertiary health-care centers. Adults asthmatics filled out a case registration form regarding age, gender, educational status, duration of asthma, and smoking history. Subjects answered The Global Initiative for Asthma (GINA) assessment of control questions and whether they had previously been mentioned an asthma action plan and benefited from it. Results: Data of 265 asthmatic adults (mean age: 48.4 (standard deviation: 13.4) years, 194 (73.2%) females) were analyzed. The asthma control state of 212 (80.0%) patients was controlled, and 53 (20.0%) patients was uncontrolled. An asthma action plan was mentioned to 91 (34.3%) of 265 patients. Among these 91 patients who were mentioned about the asthma action plan, 85 (93.4%) were given written asthma action plan, 85 (93.4%) stated that they benefited from the plan. The rate of being given an asthma action plan in illiterate patients was significantly lower than in patients with any education (p<0.001).Conclusion: Rate of mentioning an asthma action plan to asthmatics is low. Almost all patients to whom an asthma action plan is recommended benefit significantly from the plan. It is important to give patients with asthma an asthma action plan. It would be even more useful to give this plan in written form.
- 29 August 2023
- Published by Springer Nature
- p. 799-805
Predictors of Survival in Patients with Chronic Hypercapnic Respiratory Failure Receiving Noninvasive Ventilation
- 29 August 2023
- Published by Springer Nature
- p. 799-805
Predictors of Survival in Patients with Chronic Hypercapnic Respiratory Failure Receiving Noninvasive Ventilation
- 23 May 2022
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 9 (2) , 139-146
The Clinical Characteristics of Obstructive Sleep Apnea Patients with a Previous Cardiovascular Event
- 23 May 2022
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 9 (2) , 139-146
The Clinical Characteristics of Obstructive Sleep Apnea Patients with a Previous Cardiovascular Event
- Open Access
- 29 January 2022
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 4 (1) , 13-19
The Positive Airway Pressure Therapy Compliance In Mild OSAS
Introduction: This study is designed to determine the factors for predicting the PAP compliance in mild obstructive sleep apnea syndrome (OSAS) for improving the cost-effectiveness in the treatment choices of these patients. Method: The study group comprises 27 mild OSAS patients who underwent automatic positive airway pressure (APAP) titration between July 2016 and December 2017. Demographic, clinic and polysomnographic characteristics of the patients were retrospectively evaluated. Compliance with PAP treatment was defined as the usage of 5 nights/week and 4 hours/night at least. Data of compliant patients were statistically compared with non-compliant patients. Results: Most of the patients (23 patients, 85,2%) were prescribed APAP devices. Acceptable compliance at the end of the first year of therapy was achieved by 11 patients (40,2%) whereas 8 patients used PAP device 2 months at most (29,6%) The remaining 8 patients had not taken the device at all and were considered as non-adherent to PAP treatment (29,6%). The nonadherent/non-compliant group showed statistically the same demographic, clinic, and polysomnographic characteristics when compared to the compliant group. The level of maximum pressure during the titration test was lower in the compliant group (p=0,040). Conclusion: The sleep-related symptoms, scores of ESS or polysomnographic parameters can not be used to predict compliance for mild OSAS. The patients with mild OSAS, especially the ones who reach higher maximum pressure on titration test, must be followed up closely during the first 2 months of PAP treatment to detect nonadherence/non-compliance earlier.
- 29 January 2022
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 4 (1) , 13-19
Open AccessThe Positive Airway Pressure Therapy Compliance In Mild OSAS
Introduction: This study is designed to determine the factors for predicting the PAP compliance in mild obstructive sleep apnea syndrome (OSAS) for improving the cost-effectiveness in the treatment choices of these patients. Method: The study group comprises 27 mild OSAS patients who underwent automatic positive airway pressure (APAP) titration between July 2016 and December 2017. Demographic, clinic and polysomnographic characteristics of the patients were retrospectively evaluated. Compliance with PAP treatment was defined as the usage of 5 nights/week and 4 hours/night at least. Data of compliant patients were statistically compared with non-compliant patients. Results: Most of the patients (23 patients, 85,2%) were prescribed APAP devices. Acceptable compliance at the end of the first year of therapy was achieved by 11 patients (40,2%) whereas 8 patients used PAP device 2 months at most (29,6%) The remaining 8 patients had not taken the device at all and were considered as non-adherent to PAP treatment (29,6%). The nonadherent/non-compliant group showed statistically the same demographic, clinic, and polysomnographic characteristics when compared to the compliant group. The level of maximum pressure during the titration test was lower in the compliant group (p=0,040). Conclusion: The sleep-related symptoms, scores of ESS or polysomnographic parameters can not be used to predict compliance for mild OSAS. The patients with mild OSAS, especially the ones who reach higher maximum pressure on titration test, must be followed up closely during the first 2 months of PAP treatment to detect nonadherence/non-compliance earlier.
- Open Access
- 17 January 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (1) , 67-72
The relationship of obstructive sleep apnea risk with the disease severity and clinical parameters in COPD population
Aim: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) have common pathophysiological mechanisms affecting the prognosis of each other. This study aims to investigate the relationship between the presence of OSA risk and the severity of COPD and to determine the possible clinical features for OSA risk for COPD patients. Material and Method: The patients (n=181) who applied to the outpatient clinics of pulmonology between September - November 2019 with the diagnosis of COPD, were analyzed cross-sectionally. Demographic features, anthropometric measurements, comorbidities, smoking status, and severity of dyspnea, respiratory functions, and exacerbation frequency in the last year were evaluated. All patients were questioned with the Epworth sleepiness scale (ESS) for detecting excessive daytime sleepiness (EDS), and the STOP-Bang for determining the risk of OSA. Results: The rate of diabetes, waist and hip circumference measurements, median ESS score, and EDS ratio were found to be higher in patients with moderate/high OSA risk when compared to patients with low OSA risk. In the multivariate regression model; lower oxygen saturation (OR: 0.83; p=0.007) and higher ESS score (OR=1.28; p
- 17 January 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (1) , 67-72
Open AccessThe relationship of obstructive sleep apnea risk with the disease severity and clinical parameters in COPD population
Aim: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) have common pathophysiological mechanisms affecting the prognosis of each other. This study aims to investigate the relationship between the presence of OSA risk and the severity of COPD and to determine the possible clinical features for OSA risk for COPD patients. Material and Method: The patients (n=181) who applied to the outpatient clinics of pulmonology between September - November 2019 with the diagnosis of COPD, were analyzed cross-sectionally. Demographic features, anthropometric measurements, comorbidities, smoking status, and severity of dyspnea, respiratory functions, and exacerbation frequency in the last year were evaluated. All patients were questioned with the Epworth sleepiness scale (ESS) for detecting excessive daytime sleepiness (EDS), and the STOP-Bang for determining the risk of OSA. Results: The rate of diabetes, waist and hip circumference measurements, median ESS score, and EDS ratio were found to be higher in patients with moderate/high OSA risk when compared to patients with low OSA risk. In the multivariate regression model; lower oxygen saturation (OR: 0.83; p=0.007) and higher ESS score (OR=1.28; p
- Open Access
- 3 August 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (8) , 544-554
Performance of pulmonary embolism severity index in predicting long-term mortality after acute pulmonary embolism
In this study, we aimed to evaluate the accuracy of the original and simplified pulmonary embolism (PE) severity index (PESI) to predict all-cause mortality after 30 days of acute PE diagnosis up to five years within consecutive sub-periods. Adult patients diagnosed with acute PE between January 1, 2003, and June 30, 2013, were retrospectively included. Data on baseline characteristics and mortality during a five-year follow-up were collected. The study included 414 patients (Male/Female=192/222). The median age at diagnosis was 61.5 (minimum–maximum, 18–93) years. Mortality rates were 13.3% at 30 days, 21.8% at 90 days, 32.6% at one year, and 51.0% at five years. Both stratification into risk classes according to the original PESI and low vs. high-risk classification of original and simplified PESI were significantly correlated with the 30-day, 31–90-day, 91-day-one-year, and one-five-year mortality. Significant PESI predictors for mortality were history of cancer [hazard ratio (HR): 3.31, 95% confidence interval (CI): 1.64–6.68; p=0.001] and heart failure (HR: 2.35, 95% CI: 1.04–5.32, p=0.041) at 31–90-day, history of cancer (HR: 5.45, 95% CI: 2.86–10.40, p<0.001) at 91-day-one-year, advancing age (HR: 1.04, 95% CI: 1.02–1.06, p<0.001) and history of cancer (HR: 5.53, 95% CI: 3.41–8.98, p<0.001) at one-five-year after acute PE diagnosis. All-cause long-term mortality in high-risk patients with acute PE according to original or simplified PESI significantly increased up to five years of follow-up. This survival disadvantage was mainly related to cancer and comorbidities rather than acute clinical manifestations. Future prospective studies are needed to demonstrate the effect of various comorbidities on long-term mortality in these patients.
- 3 August 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (8) , 544-554
Open AccessPerformance of pulmonary embolism severity index in predicting long-term mortality after acute pulmonary embolism
In this study, we aimed to evaluate the accuracy of the original and simplified pulmonary embolism (PE) severity index (PESI) to predict all-cause mortality after 30 days of acute PE diagnosis up to five years within consecutive sub-periods. Adult patients diagnosed with acute PE between January 1, 2003, and June 30, 2013, were retrospectively included. Data on baseline characteristics and mortality during a five-year follow-up were collected. The study included 414 patients (Male/Female=192/222). The median age at diagnosis was 61.5 (minimum–maximum, 18–93) years. Mortality rates were 13.3% at 30 days, 21.8% at 90 days, 32.6% at one year, and 51.0% at five years. Both stratification into risk classes according to the original PESI and low vs. high-risk classification of original and simplified PESI were significantly correlated with the 30-day, 31–90-day, 91-day-one-year, and one-five-year mortality. Significant PESI predictors for mortality were history of cancer [hazard ratio (HR): 3.31, 95% confidence interval (CI): 1.64–6.68; p=0.001] and heart failure (HR: 2.35, 95% CI: 1.04–5.32, p=0.041) at 31–90-day, history of cancer (HR: 5.45, 95% CI: 2.86–10.40, p<0.001) at 91-day-one-year, advancing age (HR: 1.04, 95% CI: 1.02–1.06, p<0.001) and history of cancer (HR: 5.53, 95% CI: 3.41–8.98, p<0.001) at one-five-year after acute PE diagnosis. All-cause long-term mortality in high-risk patients with acute PE according to original or simplified PESI significantly increased up to five years of follow-up. This survival disadvantage was mainly related to cancer and comorbidities rather than acute clinical manifestations. Future prospective studies are needed to demonstrate the effect of various comorbidities on long-term mortality in these patients.